Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of new ...

Natera NTRA announced that its molecular residual disease (MRD) test, Signatera, received certification as a Class C device ...

Ahead of the study's publication, the data was shared at the 2026 European Society for Medical Oncology Gastrointestinal ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the National Comprehensive Cancer Network® (NCCN®) has updated its Clinical Practice ...

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces expanded availability of Precise MRD™, broadening availability to patients ...

The FDA's Breakthrough Devices Program accelerates access to promising medical devices for serious conditions, ensuring safety and effectiveness through a rigorous review process. Haystack MRD test ...

The clearance gives New York clinicians access to the Haystack MRD assay, which detects residual or recurring solid tumour ...

Quest is the largest reference laboratory to embed oncology molecular ordering into OncoEMR MPI, with projected reach to 4,700 clinicians across ~1,600 community oncology sites. Integration targets ...

Clinicians have long relied on clinical risk factors, imaging, and pathology to guide cancer surveillance and adjuvant treatment. However, even after curative-intent surgery and definitive therapy, ...

Myriad Genetics will present new data on its Precise MRD test for renal cell carcinoma at the AACR Annual Meeting. Myriad Genetics, Inc. announced that it will present new clinical data on its Precise ...

Tempus AI, Inc. Strong Buy: surging healthcare data services, MRD testing growth, and 2026–2029 revenue/margin outlook. Click ...

Add Yahoo as a preferred source to see more of our stories on Google. Haystack Oncology focuses on advancing liquid biopsy technologies. Credit: Gorodenkoff ...